Table 2.
Clinical features and psychological assessment of SLE patients.
| N (n = 42) | % | |
|---|---|---|
| Disease activity (SLEDAI) | ||
| Mild (≤ 6) | 8 | 19.0 |
| Moderate (7–12) | 12 | 28.6 |
| Severe (>12) | 22 | 52.4 |
| Organ involvement | ||
| Nervous system | 4 | 9.5 |
| Vasculitis | 2 | 4.8 |
| Articular and muscular | 16 | 38.1 |
| Renal | 21 | 50.0 |
| Cutaneous and mucous | 21 | 50.0 |
| Serositis | 20 | 47.6 |
| Hematological | 17 | 40.5 |
| Autoantibodies (+) | ||
| Anti-dsDNA antibody | 20 | 47.6 |
| Anti-Sm antibody | 26 | 61.9 |
| ARPA | 14 | 33.3 |
| Anti-nucleosome antibody | 21 | 50.0 |
| Anti-histone antibody | 21 | 50.0 |
| APLs (n = 41)* | 12 | 29.3 |
| Depression/anxiety status | ||
| Depression (HAMD ≥ 7) | 29 | 69.0 |
| Anxiety (HAMA ≥ 14) | 20 | 47.6 |
| Treatment | ||
| GCs | 42 | 100.0 |
| HCQ | 36 | 85.7 |
| CTX | 28 | 66.7 |
| MMF | 7 | 16.7 |
| CsA | 4 | 9.5 |
| MTX | 5 | 11.9 |
| LEF | 7 | 16.7 |
| Thalidomide | 7 | 16.7 |
| IVIG | 5 | 11.9 |
| Antiplatelet | 11 | 26.2 |
| Anticoagulation | 22 | 52.4 |
SLEDAI, systemic lupus erythematosus disease activity index; ARPA, Antiribosomal P protein antibodies; APLs, antiphospholipid antibodies; HAMD, Hamilton Depression Scale; HAMA, Hamilton Anxiety Scale; GCs, glucocorticoids; HCQ, hydroxychloroquine; CTX, cyclophosphamide; MMF, mycophenolate mofetil; CsA, cyclosporin A; MTX, methotrexate; LEF, leflunomide; IVIG, intravenous immunogloblin.
*
APLs was available in 41 patients.